AstraZeneca Made a Reported $10 Billion Offer for Rhythm, and the Stock Jumped 28%
A reported approach through the Alexion rare-disease unit would hand AstraZeneca a selling treatment for rare obesity - if Rhythm engages at the reported price.
Search stocks, ETFs and companies
1 sourced report attached to this file.
Verified identity
Start with the filing record
The identity and ticker come from the SEC’s official company ticker mapping. Market and editorial coverage are not inferred from that record.
- Ticker
- RYTM
- CIK
- 0001649904
- Exchange
- Nasdaq
- Universe updated
- 2026-08-22
Market price
Market price
Latest quoteOpens Google
TickerGrove coverage
Latest on RHYTHM PHARMACEUTICALS, INC.
Research foundation
Read the filing with the right frame
Company analysis
Revenue, EPS and guidance answer different earnings questions
Revenue is the top-line amount recognized from a company’s activities under its accounting policy.
Company analysis
The three financial statements describe one business from different angles
The income statement records revenue and expenses over a period.
Investing basics
Stocks, ETFs and indexes are different objects
A stock is an ownership interest in one company.